▶ 調査レポート

世界のモノクローナル抗体(mAbs)バイオシミラー市場規模・現状・予測(2021年-2027年)

• 英文タイトル:Global Monoclonal antibodies (mAbs) Biosimilars Market Size, Status and Forecast 2021-2027

QYResearchが調査・発行した産業分析レポートです。世界のモノクローナル抗体(mAbs)バイオシミラー市場規模・現状・予測(2021年-2027年) / Global Monoclonal antibodies (mAbs) Biosimilars Market Size, Status and Forecast 2021-2027 / QYR2104Z3904資料のイメージです。• レポートコード:QYR2104Z3904
• 出版社/出版日:QYResearch / 2021年4月15日
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、96ページ
• 納品方法:Eメール(納期:3日)
• 産業分類:医薬品、ヘルスケア
• 販売価格(消費税別)
  Single User¥577,200 (USD3,900)▷ お問い合わせ
  Multi User/Five User¥865,800 (USD5,850)▷ お問い合わせ
  Enterprise License(同一法人内共有可)¥1,154,400 (USD7,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
QYResearch社発行の本調査資料では、モノクローナル抗体(mAbs)バイオシミラーのグローバル市場(2016年~2027年)について調べ、市場動向、主要企業の市場シェア、種類別市場規模(エリスロポエチン(EPO)、ヒト成長ホルモン(HGH)、顆粒球コロニー刺激因子(G-CSF)、モノクローナル抗体(mAb)、インスリン、インターフェロン(IFN)、その他)、用途別市場規模(抗がん、抗炎症/自己免疫)、主要地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、関連企業情報などを掲載しています。
・市場概要
・モノクローナル抗体(mAbs)バイオシミラーの市場動向
・企業の競争状況、市場シェア
・モノクローナル抗体(mAbs)バイオシミラーの種類別市場規模(エリスロポエチン(EPO)、ヒト成長ホルモン(HGH)、顆粒球コロニー刺激因子(G-CSF)、モノクローナル抗体(mAb)、インスリン、インターフェロン(IFN)、その他)
・モノクローナル抗体(mAbs)バイオシミラーの用途別市場規模(抗がん、抗炎症/自己免疫)
・モノクローナル抗体(mAbs)バイオシミラーの北米市場規模2016-2027(アメリカ、カナダ)
・モノクローナル抗体(mAbs)バイオシミラーのヨーロッパ市場規模2016-2027(ドイツ、フランス、イギリス等)
・モノクローナル抗体(mAbs)バイオシミラーのアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・モノクローナル抗体(mAbs)バイオシミラーの中南米市場規模2016-2027(メキシコ、ブラジル)
・モノクローナル抗体(mAbs)バイオシミラーの中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Biocon、Celltrion、Dr. Reddy's Laboratories、Hospira、3SBio、Accord Healthcare、AET Biotech、Allergan、Amega Biotech、Others)
・結論

A biosimilar medicine is a medicinal product of biological origin that is produced in a living organism following a procedure equivalent to a biological drug and adhering to the same quality criteria, hence the name biosimilars. In short, they are biological drugs that are “equivalent” in terms of quality, efficacy and safety to an innovative reference medicinal product.
According to the report, one driver that will lead to the growth of this market is the rise in number of patent expiries.

Market Analysis and Insights: Global Monoclonal antibodies (mAbs) Biosimilars Market
The global Monoclonal antibodies (mAbs) Biosimilars market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Monoclonal antibodies (mAbs) Biosimilars market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Monoclonal antibodies (mAbs) Biosimilars market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Monoclonal antibodies (mAbs) Biosimilars market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Monoclonal antibodies (mAbs) Biosimilars market.

Global Monoclonal antibodies (mAbs) Biosimilars Scope and Market Size
Monoclonal antibodies (mAbs) Biosimilars market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Monoclonal antibodies (mAbs) Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Erythropoietin (EPO)
Human Growth Hormone (HGH)
Granulocyte- Colony Stimulating Factor (G-CSF)
Monoclonal Antibody (mAb)
Insulin
Interferon (IFN)
Others

Segment by Application
Anti-Cancer
Anti-Inflammatory/Autoimmune

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Biocon
Celltrion
Dr. Reddy’s Laboratories
Hospira
3SBio
Accord Healthcare
AET Biotech
Allergan
Amega Biotech

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Erythropoietin (EPO)
1.2.3 Human Growth Hormone (HGH)
1.2.4 Granulocyte- Colony Stimulating Factor (G-CSF)
1.2.5 Monoclonal Antibody (mAb)
1.2.6 Insulin
1.2.7 Interferon (IFN)
1.2.8 Others
1.3 Market by Application
1.3.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Anti-Cancer
1.3.3 Anti-Inflammatory/Autoimmune
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Perspective (2016-2027)
2.2 Monoclonal antibodies (mAbs) Biosimilars Growth Trends by Regions
2.2.1 Monoclonal antibodies (mAbs) Biosimilars Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Monoclonal antibodies (mAbs) Biosimilars Historic Market Share by Regions (2016-2021)
2.2.3 Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Regions (2022-2027)
2.3 Monoclonal antibodies (mAbs) Biosimilars Industry Dynamic
2.3.1 Monoclonal antibodies (mAbs) Biosimilars Market Trends
2.3.2 Monoclonal antibodies (mAbs) Biosimilars Market Drivers
2.3.3 Monoclonal antibodies (mAbs) Biosimilars Market Challenges
2.3.4 Monoclonal antibodies (mAbs) Biosimilars Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Revenue
3.1.1 Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Revenue (2016-2021)
3.1.2 Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Players (2016-2021)
3.2 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Monoclonal antibodies (mAbs) Biosimilars Revenue
3.4 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio
3.4.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Monoclonal antibodies (mAbs) Biosimilars Revenue in 2020
3.5 Monoclonal antibodies (mAbs) Biosimilars Key Players Head office and Area Served
3.6 Key Players Monoclonal antibodies (mAbs) Biosimilars Product Solution and Service
3.7 Date of Enter into Monoclonal antibodies (mAbs) Biosimilars Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Type
4.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Type (2016-2021)
4.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Type (2022-2027)

5 Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Application
5.1 Global Monoclonal antibodies (mAbs) Biosimilars Historic Market Size by Application (2016-2021)
5.2 Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Monoclonal antibodies (mAbs) Biosimilars Market Size (2016-2027)
6.2 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type
6.2.1 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2016-2021)
6.2.2 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2022-2027)
6.2.3 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2016-2027)
6.3 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application
6.3.1 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2016-2021)
6.3.2 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2022-2027)
6.3.3 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2016-2027)
6.4 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country
6.4.1 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2016-2021)
6.4.2 North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size (2016-2027)
7.2 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Type
7.2.1 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2016-2021)
7.2.2 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2022-2027)
7.2.3 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2016-2027)
7.3 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Application
7.3.1 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2016-2021)
7.3.2 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2022-2027)
7.3.3 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2016-2027)
7.4 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country
7.4.1 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2016-2021)
7.4.2 Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size (2016-2027)
8.2 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Type
8.2.1 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2016-2027)
8.3 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Application
8.3.1 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2016-2027)
8.4 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region
8.4.1 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size (2016-2027)
9.2 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type
9.2.1 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2016-2021)
9.2.2 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2022-2027)
9.2.3 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2016-2027)
9.3 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application
9.3.1 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2016-2021)
9.3.2 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2022-2027)
9.3.3 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2016-2027)
9.4 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country
9.4.1 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2016-2021)
9.4.2 Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size (2016-2027)
10.2 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Type
10.2.1 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2016-2027)
10.3 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Application
10.3.1 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2016-2027)
10.4 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country
10.4.1 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Biocon
11.1.1 Biocon Company Details
11.1.2 Biocon Business Overview
11.1.3 Biocon Monoclonal antibodies (mAbs) Biosimilars Introduction
11.1.4 Biocon Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021)
11.1.5 Biocon Recent Development
11.2 Celltrion
11.2.1 Celltrion Company Details
11.2.2 Celltrion Business Overview
11.2.3 Celltrion Monoclonal antibodies (mAbs) Biosimilars Introduction
11.2.4 Celltrion Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021)
11.2.5 Celltrion Recent Development
11.3 Dr. Reddy’s Laboratories
11.3.1 Dr. Reddy’s Laboratories Company Details
11.3.2 Dr. Reddy’s Laboratories Business Overview
11.3.3 Dr. Reddy’s Laboratories Monoclonal antibodies (mAbs) Biosimilars Introduction
11.3.4 Dr. Reddy’s Laboratories Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021)
11.3.5 Dr. Reddy’s Laboratories Recent Development
11.4 Hospira
11.4.1 Hospira Company Details
11.4.2 Hospira Business Overview
11.4.3 Hospira Monoclonal antibodies (mAbs) Biosimilars Introduction
11.4.4 Hospira Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021)
11.4.5 Hospira Recent Development
11.5 3SBio
11.5.1 3SBio Company Details
11.5.2 3SBio Business Overview
11.5.3 3SBio Monoclonal antibodies (mAbs) Biosimilars Introduction
11.5.4 3SBio Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021)
11.5.5 3SBio Recent Development
11.6 Accord Healthcare
11.6.1 Accord Healthcare Company Details
11.6.2 Accord Healthcare Business Overview
11.6.3 Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Introduction
11.6.4 Accord Healthcare Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021)
11.6.5 Accord Healthcare Recent Development
11.7 AET Biotech
11.7.1 AET Biotech Company Details
11.7.2 AET Biotech Business Overview
11.7.3 AET Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction
11.7.4 AET Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021)
11.7.5 AET Biotech Recent Development
11.8 Allergan
11.8.1 Allergan Company Details
11.8.2 Allergan Business Overview
11.8.3 Allergan Monoclonal antibodies (mAbs) Biosimilars Introduction
11.8.4 Allergan Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021)
11.8.5 Allergan Recent Development
11.9 Amega Biotech
11.9.1 Amega Biotech Company Details
11.9.2 Amega Biotech Business Overview
11.9.3 Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Introduction
11.9.4 Amega Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021)
11.9.5 Amega Biotech Recent Development
11.10 Others
11.10.1 Others Company Details
11.10.2 Others Business Overview
11.10.3 Others Monoclonal antibodies (mAbs) Biosimilars Introduction
11.10.4 Others Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021)
11.10.5 Others Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Erythropoietin (EPO)
Table 3. Key Players of Human Growth Hormone (HGH)
Table 4. Key Players of Granulocyte- Colony Stimulating Factor (G-CSF)
Table 5. Key Players of Monoclonal Antibody (mAb)
Table 6. Key Players of Insulin
Table 7. Key Players of Interferon (IFN)
Table 8. Key Players of Others
Table 9. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 11. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Regions (2016-2021) & (US$ Million)
Table 12. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Regions (2016-2021)
Table 13. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 14. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Regions (2022-2027)
Table 15. Monoclonal antibodies (mAbs) Biosimilars Market Trends
Table 16. Monoclonal antibodies (mAbs) Biosimilars Market Drivers
Table 17. Monoclonal antibodies (mAbs) Biosimilars Market Challenges
Table 18. Monoclonal antibodies (mAbs) Biosimilars Market Restraints
Table 19. Global Monoclonal antibodies (mAbs) Biosimilars Revenue by Players (2016-2021) & (US$ Million)
Table 20. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Players (2016-2021)
Table 21. Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Monoclonal antibodies (mAbs) Biosimilars as of 2020)
Table 22. Ranking of Global Top Monoclonal antibodies (mAbs) Biosimilars Companies by Revenue (US$ Million) in 2020
Table 23. Global 5 Largest Players Market Share by Monoclonal antibodies (mAbs) Biosimilars Revenue (CR5 and HHI) & (2016-2021)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Monoclonal antibodies (mAbs) Biosimilars Product Solution and Service
Table 26. Date of Enter into Monoclonal antibodies (mAbs) Biosimilars Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 29. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2016-2021)
Table 30. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 31. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 32. Global Monoclonal antibodies (mAbs) Biosimilars Market Size Share by Application (2016-2021) & (US$ Million)
Table 33. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2016-2021)
Table 34. Global Monoclonal antibodies (mAbs) Biosimilars Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 35. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 36. North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 37. North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2022-2027) & (US$ Million)
Table 38. North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2016-2021) (US$ Million)
Table 39. North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2022-2027) & (US$ Million)
Table 40. North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2016-2021) & (US$ Million)
Table 41. North America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2022-2027) & (US$ Million)
Table 42. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 43. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2022-2027) & (US$ Million)
Table 44. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2016-2021) (US$ Million)
Table 45. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2022-2027) & (US$ Million)
Table 46. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2016-2021) & (US$ Million)
Table 47. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 49. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2016-2021) (US$ Million)
Table 51. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2022-2027) & (US$ Million)
Table 52. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2016-2021) & (US$ Million)
Table 53. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size by Region (2022-2027) & (US$ Million)
Table 54. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 55. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2022-2027) & (US$ Million)
Table 56. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2016-2021) (US$ Million)
Table 57. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2022-2027) & (US$ Million)
Table 58. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2016-2021) & (US$ Million)
Table 59. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2016-2021) (US$ Million)
Table 61. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Type (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2016-2021) (US$ Million)
Table 63. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Application (2022-2027) & (US$ Million)
Table 64. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2016-2021) & (US$ Million)
Table 65. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size by Country (2022-2027) & (US$ Million)
Table 66. Biocon Company Details
Table 67. Biocon Business Overview
Table 68. Biocon Monoclonal antibodies (mAbs) Biosimilars Product
Table 69. Biocon Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021) & (US$ Million)
Table 70. Biocon Recent Development
Table 71. Celltrion Company Details
Table 72. Celltrion Business Overview
Table 73. Celltrion Monoclonal antibodies (mAbs) Biosimilars Product
Table 74. Celltrion Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021) & (US$ Million)
Table 75. Celltrion Recent Development
Table 76. Dr. Reddy's Laboratories Company Details
Table 77. Dr. Reddy's Laboratories Business Overview
Table 78. Dr. Reddy's Laboratories Monoclonal antibodies (mAbs) Biosimilars Product
Table 79. Dr. Reddy's Laboratories Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021) & (US$ Million)
Table 80. Dr. Reddy's Laboratories Recent Development
Table 81. Hospira Company Details
Table 82. Hospira Business Overview
Table 83. Hospira Monoclonal antibodies (mAbs) Biosimilars Product
Table 84. Hospira Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021) & (US$ Million)
Table 85. Hospira Recent Development
Table 86. 3SBio Company Details
Table 87. 3SBio Business Overview
Table 88. 3SBio Monoclonal antibodies (mAbs) Biosimilars Product
Table 89. 3SBio Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021) & (US$ Million)
Table 90. 3SBio Recent Development
Table 91. Accord Healthcare Company Details
Table 92. Accord Healthcare Business Overview
Table 93. Accord Healthcare Monoclonal antibodies (mAbs) Biosimilars Product
Table 94. Accord Healthcare Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021) & (US$ Million)
Table 95. Accord Healthcare Recent Development
Table 96. AET Biotech Company Details
Table 97. AET Biotech Business Overview
Table 98. AET Biotech Monoclonal antibodies (mAbs) Biosimilars Product
Table 99. AET Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021) & (US$ Million)
Table 100. AET Biotech Recent Development
Table 101. Allergan Company Details
Table 102. Allergan Business Overview
Table 103. Allergan Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021) & (US$ Million)
Table 104. Allergan Recent Development
Table 105. Amega Biotech Company Details
Table 106. Amega Biotech Business Overview
Table 107. Amega Biotech Monoclonal antibodies (mAbs) Biosimilars Product
Table 108. Amega Biotech Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021) & (US$ Million)
Table 109. Amega Biotech Recent Development
Table 110. Others Company Details
Table 111. Others Business Overview
Table 112. Others Monoclonal antibodies (mAbs) Biosimilars Product
Table 113. Others Revenue in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021) & (US$ Million)
Table 114. Others Recent Development
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Type: 2020 VS 2027
Figure 2. Erythropoietin (EPO) Features
Figure 3. Human Growth Hormone (HGH) Features
Figure 4. Granulocyte- Colony Stimulating Factor (G-CSF) Features
Figure 5. Monoclonal Antibody (mAb) Features
Figure 6. Insulin Features
Figure 7. Interferon (IFN) Features
Figure 8. Others Features
Figure 9. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Application: 2020 VS 2027
Figure 10. Anti-Cancer Case Studies
Figure 11. Anti-Inflammatory/Autoimmune Case Studies
Figure 12. Monoclonal antibodies (mAbs) Biosimilars Report Years Considered
Figure 13. Global Monoclonal antibodies (mAbs) Biosimilars Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Monoclonal antibodies (mAbs) Biosimilars Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Regions: 2020 VS 2027
Figure 16. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Regions (2022-2027)
Figure 17. Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Players in 2020
Figure 18. Global Top Monoclonal antibodies (mAbs) Biosimilars Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Monoclonal antibodies (mAbs) Biosimilars as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Monoclonal antibodies (mAbs) Biosimilars Revenue in 2020
Figure 20. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2016-2021)
Figure 21. Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type (2022-2027)
Figure 22. North America Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Monoclonal antibodies (mAbs) Biosimilars Market Share by Type (2016-2027)
Figure 24. North America Monoclonal antibodies (mAbs) Biosimilars Market Share by Application (2016-2027)
Figure 25. North America Monoclonal antibodies (mAbs) Biosimilars Market Share by Country (2016-2027)
Figure 26. United States Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Monoclonal antibodies (mAbs) Biosimilars Market Share by Type (2016-2027)
Figure 30. Europe Monoclonal antibodies (mAbs) Biosimilars Market Share by Application (2016-2027)
Figure 31. Europe Monoclonal antibodies (mAbs) Biosimilars Market Share by Country (2016-2027)
Figure 32. Germany Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Monoclonal antibodies (mAbs) Biosimilars Market Share by Region (2016-2027)
Figure 42. China Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Share by Type (2016-2027)
Figure 50. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Share by Application (2016-2027)
Figure 51. Latin America Monoclonal antibodies (mAbs) Biosimilars Market Share by Country (2016-2027)
Figure 52. Mexico Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Monoclonal antibodies (mAbs) Biosimilars Market Share by Country (2016-2027)
Figure 58. Turkey Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Monoclonal antibodies (mAbs) Biosimilars Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Biocon Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021)
Figure 62. Celltrion Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021)
Figure 63. Dr. Reddy's Laboratories Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021)
Figure 64. Hospira Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021)
Figure 65. 3SBio Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021)
Figure 66. Accord Healthcare Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021)
Figure 67. AET Biotech Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021)
Figure 68. Allergan Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021)
Figure 69. Amega Biotech Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021)
Figure 70. Others Revenue Growth Rate in Monoclonal antibodies (mAbs) Biosimilars Business (2016-2021)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed